Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 3054–3055.

https://doi.org/10.1182/blood-2022-159507

Published: 2022

Journal Articles

Mesenchymal Stromal Cells (MSCs) from Myelodysplastic Syndromes (MDS) Are Not Clonally Mutated I n Vivo

Johann-Christoph Jann, Maximilian Mossner, Vladimir Riabov, Eva Altrock, Nanni Schmitt, Johanna Flach, Qingyu Xu, Verena Nowak, Julia Obländer, Iris Palme, Nadine Weimer, Alexander Streuer, Ahmed Jawhar, Ali Darwich, Georgia Metzgeroth, Florian Nolte, Wolf-Karsten Hofmann, Daniel Nowak

Blood (2021) 138 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2021-150244

Published: 2021

Journal Articles

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

Jacqueline S. Garcia, MD, Andrew H. Wei, Uma Borate, Chun Yew Fong, MBBS, PhD FRACP, FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Joseph G. Jurcic, MD, Meagan A. Jacoby, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Ilona Cunningham, MBBS, FRACP, FRCPA, Ying Zhou, PhD, Bo Tong, PhD, Leah Hogdal, PhD, Rajesh Kamalakar, MS, Jessica E. Hutti, PhD, Steve Kye, MD MPH, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 55–57.

https://doi.org/10.1182/blood-2020-139492

Published: 2020

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Blood (2019) 134 (Supplement_1): 565.

https://doi.org/10.1182/blood-2019-124994

Published: 2019

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Andrew H. Wei, Jacqueline S Garcia, MD, Uma Borate, MD, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Pierre Peterlin, Joseph G. Jurcic, MD, Guillermo Garcia-Manero, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Jason Harb, PhD, Poonam Tanwani, BSc, Johannes E. Wolff, MD, Meagan Jacoby, MD

Blood (2019) 134 (Supplement_1): 568.

https://doi.org/10.1182/blood-2019-124437

Published: 2019

Journal Articles

Comparison of Four Different Humanized Hematopoietic Niche Xenotransplantation Methods to Engraft Myelodysplastic Syndromes (MDS)

Blood (2019) 134 (Supplement_1): 4227.

https://doi.org/10.1182/blood-2019-128075

Published: 2019

Journal Articles

R-Loops-Induced ATR Signaling As a Potential Therapeutic Target in Myelodysplastic Syndrome

Johann-Christoph Jann, Johanna Flach, PhD, Antje Knaflic, Eva Altrock, PhD, Nanni Schmitt, MSc, Alexander Streuer, Justine Danner, Franziska Hofmann, Verena Nowak, Nina Draeger, Julia Obländer, Iris Palme, Patrick Wuchter, MD, Ahmed Jawhar, MD, Georgia Metzgeroth, MD, Florian Nolte, MD, Wolf-Karsten Hofmann, MD PhD, Daniel Nowak, MD

Blood (2019) 134 (Supplement_1): 4218.

https://doi.org/10.1182/blood-2019-126431

Published: 2019

Journal Articles

Placebo Controlled Functional Analysis of Eltrombopag in a Preclinical Xenograft Model of Myelodysplastic Syndromes (MDS)

Nanni Schmitt, MSc, Eva Altrock, PhD, Johann-Christoph Jann, MD, Johanna Flach, PhD, Carla Sens-Albert, PhD, Justine Danner, Stefanie Uhlig, Jovita Pressler, Iris Palme, Verena Nowak, Julia Obländer, Lena Drangmeister, MD, Franziska La Meir, MD, Georgia Metzgeroth, MD, Florian Nolte, MD, Wolf-Karsten Hofmann, Daniel Nowak, MD

Blood (2018) 132 (Supplement 1): 942.

https://doi.org/10.1182/blood-2018-99-116341

Published: 2018

Journal Articles

Prospective Multicenter Phase 3 Study Comparing 5-Azacytidine (5-Aza) Induction Followed By Allogeneic Stem Cell Transplantation Versus Continuous 5-Aza According to Donor Availability in Elderly MDS Patients (55-70 years) (VidazaAllo Study)

Blood (2018) 132 (Supplement 1): 208.

https://doi.org/10.1182/blood-2018-99-115932

Published: 2018

Journal Articles

Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy

Blood (2017) 130 (Supplement 1): 2916.

https://doi.org/10.1182/blood.V130.Suppl_1.2916.2916

Published: 2017

Journal Articles

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Uwe Platzbecker, MD, Eva Lengfelder, MD, Katharina S Goetze, MD, Christoph Röllig, MD, Michael Kramer, Michaela Sauer, Nadine Albers, Michael Heuser, Hartmut Link, MD PhD, Kerstin Schäfer-Eckart, MD, Sonja Martin, MD, Stefan W. Krause, MD, Mathias Hänel, MD, Tilmann Bochtler, MD, Andreas Jakob, MD, Albrecht Reichle, MD, Harald Biersack, MD, Claudia D. Baldus, MD, Martin Goerner, MD, Nadezda Basara, MD, Joerg Mezger, MD, Ralph Naumann, MD, Dorit Kuerschner, MD, Maike de Wit, Florian Nolte, MD, Mark Ringhoffer, MD, Hans-Joachim Tischler, MD, Jochen Greiner, Stephan Kremers, Sigrid Machherndl-Spandl, MD, Elisabeth Koller, MD, Mohammad Amen Wattad, MD, Gregor Aschauer, MD, Markus Radsak, MD, Thomas Kubin, MD, Helmut Salih, MD, Frank Heits, MD, Dominik Wolf, MD, Christian Thiede, MD, Hubert Serve, MD, Ulrich Duehrsen, MD, Andreas Hochhaus, MD, Tim H. Brümmendorf, MD, Martin Bornhäuser, MD, Hartmut Döhner, MD, Gerhard Ehninger, MD, Richard F. Schlenk, MD

Blood (2016) 128 (22): 2815.

https://doi.org/10.1182/blood.V128.22.2815.2815

Published: 2016

Journal Articles

RNA Sequencing of Bone Marrow Derived Mesenchymal Stromal Cells (MSCs) of Healthy Young, Healthy Old and Patients with Myelodysplastic Syndrome (MDS) Reveals Transcriptomic Changes upon Aging of the Niche and Onset of MDS

Johann-Christoph Jann, Maximilian Mossner, Florian Nolte, MD, Tobias Boch, MD, Verena Nowak, Iris Palme, Julia Obländer, Jovita Pressler, Christina Xanthopoulos, Henning Röhl, MD, Wolf-Karsten Hofmann, MD, Daniel Nowak, MD

Blood (2016) 128 (22): 4300.

https://doi.org/10.1182/blood.V128.22.4300.4300

Published: 2016

Journal Articles

Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk MDS: Results from a Phase I Study

Tobias Boch, MD, Thomas Luft, MD PhD, Maximilian Mossner, Johann-Christoph Jann, Daniel Nowak, MD, Christine Folz, Jennifer Klemmer, Susanne Brendel, Harald Fricke, MD, Claudia Kunz, PhD, Wolf-Karsten Hofmann, MD, Florian Nolte, MD

Blood (2016) 128 (22): 228.

https://doi.org/10.1182/blood.V128.22.228.228

Published: 2016

Journal Articles

Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure

Blood (2016) 128 (9): 1246–1259.

https://doi.org/10.1182/blood-2015-11-679167

Published: 2016

Includes: Supplemental data

Journal Articles

Different Impact of Expression Levels of IGFBP2 and IGFBP7 on Survival and Relapse Rate in Acute Promyelocytic Leukemia

Anna Hecht, Daniel Nowak, MD, Florian Nolte, Verena Nowak, Julia Oblaender, Thomas Buechner, Karsten Spiekermann, Wolf-Karsten Hofmann, MD, Eva Lengfelder, MD

Blood (2015) 126 (23): 1382.

https://doi.org/10.1182/blood.V126.23.1382.1382

Published: 2015

Journal Articles

Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS)

Maximilian Mossner, Alexandra Stoehr, Johann-Christoph Jann, Florian Nolte, MD, Verena Nowak, Julia Oblaender, Jovita Pressler, Christina Xanthopoulos, Iris Palme, Claudia D Baldus, MD, Torsten Schulze, MD, Tobias Boch, MD, Georgia Metzgeroth, MD, Martin Neumann, MD, Wolf-Karsten Hofmann, MD, Daniel Nowak, MD

Blood (2015) 126 (23): 2859.

https://doi.org/10.1182/blood.V126.23.2859.2859

Published: 2015

Journal Articles

Influence of the Insertion Site on Central Venous Catheter Related Complications in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation, High Dose Therapy or Induction Therapy for Acute Leukemia

Daniela Heidenreich, Eleonore Muetzel, Sebastian Kreil, Florian Nolte, Melanie Faust, Mohamad Jawhar, Anna Hecht, Wolf-Karsten Hofmann, Stefan A. Klein

Blood (2015) 126 (23): 1919.

https://doi.org/10.1182/blood.V126.23.1919.1919

Published: 2015

Journal Articles

Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment

Blood (2015) 126 (23): 2891.

https://doi.org/10.1182/blood.V126.23.2891.2891

Published: 2015

Journal Articles

Quantitative Analysis of Patient-Specific Lesions in Primary and Xenografted Myelodysplastic Syndromes Reveals Complex Hierarchies and Subclonal Diversity That Evolve during Disease Progression

Blood (2014) 124 (21): 4604.

https://doi.org/10.1182/blood.V124.21.4604.4604

Published: 2014

Journal Articles

Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R

Julie Schanz, MD PhD, Friederike Braulke, MD, Ghulam J. Mufti, MD PhD, Elena Crisà, Austin Kulasekararaj, Kathrin Nachtkamp, MD, Ulrich Germing, Stefan Schmitz, MD PhD, Peter Haas, MD, Michael Lübbert, Catharina Müller-Thomas, MD, Katharina Götze, Uwe Platzbecker, MD, Florian Nolte, Wolf-Karsten Hofmann, MD PhD, Detlef Haase

Blood (2014) 124 (21): 4656.

https://doi.org/10.1182/blood.V124.21.4656.4656

Published: 2014

NARROW

Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms

Mesenchymal Stromal Cells (MSCs) from Myelodysplastic Syndromes (MDS) Are Not Clonally Mutated I n Vivo

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Comparison of Four Different Humanized Hematopoietic Niche Xenotransplantation Methods to Engraft Myelodysplastic Syndromes (MDS)

R-Loops-Induced ATR Signaling As a Potential Therapeutic Target in Myelodysplastic Syndrome

Placebo Controlled Functional Analysis of Eltrombopag in a Preclinical Xenograft Model of Myelodysplastic Syndromes (MDS)

Prospective Multicenter Phase 3 Study Comparing 5-Azacytidine (5-Aza) Induction Followed By Allogeneic Stem Cell Transplantation Versus Continuous 5-Aza According to Donor Availability in Elderly MDS Patients (55-70 years) (VidazaAllo Study)

Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

RNA Sequencing of Bone Marrow Derived Mesenchymal Stromal Cells (MSCs) of Healthy Young, Healthy Old and Patients with Myelodysplastic Syndrome (MDS) Reveals Transcriptomic Changes upon Aging of the Niche and Onset of MDS

Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk MDS: Results from a Phase I Study

Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure

Different Impact of Expression Levels of IGFBP2 and IGFBP7 on Survival and Relapse Rate in Acute Promyelocytic Leukemia

Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS)

Influence of the Insertion Site on Central Venous Catheter Related Complications in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation, High Dose Therapy or Induction Therapy for Acute Leukemia

Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment

Quantitative Analysis of Patient-Specific Lesions in Primary and Xenografted Myelodysplastic Syndromes Reveals Complex Hierarchies and Subclonal Diversity That Evolve during Disease Progression

Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only